Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products “The ...

The FDA has granted expanded indications for use of gadobutrol (Gadavist; Bayer) injection, permitting its use in cardiac MR to assess myocardial perfusion and late gadolinium enhancement in adults ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it will introduce a portfolio of generic contrast media agents in the United States, starting immediately with the launch of ...

Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2 No significant financial relationships to disclose. This is ...

Centargo compatible with Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol) Follows recent FDA clearance to expand the use of ...

Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...

Expanded use of Gadavist is specific to detecting and visualizing areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in pediatric patients under the age ...

We are looking for volunteers to undergo magnetic resonance imaging (MRI) scans of the brain, with gadolinium-based contrast agent injection. Participants will be paid $80. The total scan duration is ...

CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...

Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent ...